N-(3-溴苯基)甲烷磺酰胺 | 83922-51-4

• 物质功能分类: 有机原料 - 氨基化合物 - 酰胺类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(3-溴苯基)甲烷磺酰胺
• 中文别名: N-(3-溴苯基)甲基磺酰胺
• 英文名称: 3-(methylsulfonyl)amino-1-bromo-benzene
• 英文别名: N-(3-bromophenyl)methanesulfonamide；3-bromo methanesulphonanilide；3-methylsulfonylamino-1-bromobenzene；N-(3-bromo-phenyl)methanesulfonamide
• CAS: 83922-51-4
• 化学式: C₇H₈BrNO₂S
• mdl: MFCD01213915
• 分子量: 250.116
• InChiKey: DCAVLRMJGJXYMZ-UHFFFAOYSA-N

物化性质

• 沸点：
  330.7±44.0 °C(Predicted)
• 密度：
  1.711±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2935009090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥

反应信息

• 作为反应物：
  描述：

  N-(3-溴苯基)甲烷磺酰胺 在 三氟甲磺酸 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 0.17h， 生成 7-溴喹啉
  参考文献：
  名称：

  Tokuyama, Hidetoshi; Sato, Masashi; Ueda, Toshihiro, Heterocycles, 2001, vol. 54, # 1, p. 105 - 108

  摘要：

  DOI：
• 作为产物：
  描述：

  甲基磺酰氯 、 间溴苯胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-(3-溴苯基)甲烷磺酰胺
  参考文献：
  名称：

  钯催化级联SP 2 C-H键的官能允许一锅访问4-芳基-1,2,3,4-四氢喹啉从Ñ -Allyl- Ñ -arylsulfonamides

  摘要：

  我们已经开发了钯催化的级联反应，可以从N-烯丙基-N-芳基磺酰胺和苯磺酰氯有效合成4-芳基-1,2,3,4-四氢喹啉。在此转换中，通过激活C（sp 2）-H键形成了两个C（sp 2）-C（sp 3）键。该反应使用容易获得的催化剂PdCl 2进行，其中Li 2 CO 3为廉价的碱，CuBr为添加剂，并且在两个反应伙伴上都可以耐受多种取代基。

  DOI：

  10.1021/acscatal.6b02586

文献信息

• Pyrazinyl-substituted naphthalene derivatives
  申请人：——

  公开号：US20010004669A1

  公开（公告）日：2001-06-21

  Compounds of the formula 1 where R 1 is of the formulae 2 R 2 is —R 4 , —O—R 4 , —O—S (O) 2 —R 4 , —NR 4 R 5 , R 4 —(CH 2 ) b —NH(C═X)—(CH 2 )—, R 4 —(CH 2 ) b —O(C═O)NH—(CH 2 ) c —(C═O)NH—, R 4 (C═O)NH—(C═O)NH—, —(CH 2 ) b —NH(C═X)—(CH 2 ) c —R 4 , R 4 —(CH 2 ) b —O(C═)—(CH 2 ) c —, —(CH 2 ) b —O(C═O)—(CH 2 ) c —R 4 , —NH(C═X)NH—R 4 , R 4 —O(C═O)O—, —O(C═)NH—R 4 , R 4 —O(C═O)NH—, —(CH 2 ) b —(C═0)—(CH 2 ) c —R 4 , —NH—S(O) 2 —R 4 , —C(OH)R 4 R 5 , —CH(OH)—R 4 , —(C═O)—NR 4 R 5 , —CN, —NO 2 , substituted C 1 to C 6 alkyl, substituted or unsubstituted C 1 to C 6 alkenyl, or substituted or unsubstituted C 1 to C 6 alkynyl, said substituted moieties substituted with a moiety of the formulae —R 4 , —R 4 R 5 , —O—R 4 , or —S(O) d —R 4 . These compounds are useful psychotherapeutics and are potent serotonin (5-HT 1 ) agonists and antagonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotranmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

  公式1的化合物，其中R1是公式2，R2是—R4，—O—R4，—O—S(O)2—R4，—NR4R5，R4—(CH2)b—NH(C═X)—(CH2)c—，R4—(CH2)b—O(C═O)NH—(CH2)c—(C═O)NH—，R4(C═O)NH—(C═O)NH—，—(CH2)b—NH(C═X)—(CH2)c—R4，R4—(CH2)b—O(C═)—(CH2)c—，—(CH2)b—O(C═O)—(CH2)c—R4，—NH(C═X)NH—R4，R4—O(C═O)O—，—O(C═)NH—R4，R4—O(C═O)NH—，—(CH2)b—(C═O)—(CH2)c—R4，—NH—S(O)2—R4，—C(OH)R4R5，—CH(OH)—R4，—(C═O)—NR4R5，—CN，—NO2，取代的C1至C6烷基，取代或未取代的C1至C6烯基，或取代或未取代的C1至C6炔基，所述取代基团被公式—R4，—R4R5，—O—R4或—S(O)d—R4的基团取代。这些化合物是有用的精神治疗剂，并且是强效的血清素（5-HT1）激动剂和拮抗剂，可用于治疗抑郁症、焦虑症、饮食失调、肥胖、药物滥用、丛集性头痛、偏头痛、疼痛和慢性阵发性偏头痛以及与血管疾病相关的头痛，以及其他由血清素神经传递不足引起的疾病。这些化合物还可用作中枢作用抗高血压药和血管扩张剂。
• Compositions containing sertraline and a 5-HT.sub.1D receptor agonist or
  申请人：Pfizer Inc.

  公开号：US05597826A1

  公开（公告）日：1997-01-28

  The present invention relates to novel compositions containing the serotonin selective re-uptake inhibitor (SSRI), preferably (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine, and an agonist or antagonist of the serotonin 1 (5-HT.sub.1) receptor and to the use of such compositions for treating or preventing a condition selected from mood disorders, including depression, seasonal affective disorders and dysthmia, anxiety disorders including generalized anxiety disorder and panic disorder; agoraphobia, avoidant personality disorder; social phobia; obsessive compulsive disorder; post-traumatic stress disorder; memory disorders including dementia, amnestic disorders and age-associated memory impairment; disorders of eating behavior, including anorexia nervosa and bulimia nervosa; obesity; cluster headache; migraine; pain; Alzheimer's disease; chronic paroxysmal hemicrania; headache associated with vascular disorders; Parkinson's disease, including dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; endocrine disorders such as hyperprolactinaemia; vasospasm (particularly in the cerebral vasculature); hypertension; disorders in the gastrointestinal tract where changes in motility and secretion are involved; sexual dysfunction, including premature ejaculation; and chemical dependencies.

  本发明涉及包含选择性5-羟色胺再摄取抑制剂（SSRI），优选（1S-顺）-4-(3,4-二氯苯基)-1,2,3,4-四氢-N-甲基-1-萘胺，以及5-羟色胺1（5-HT1）受体的激动剂或拮抗剂的新组合物，以及使用这样的组合物治疗或预防情绪障碍，包括抑郁症、季节性情感障碍和情绪恶劣，焦虑障碍，包括广泛性焦虑障碍和恐慌障碍；恐旷症，回避性人格障碍；社交恐惧症；强迫症；创伤后应激障碍；记忆障碍，包括痴呆、遗忘障碍和与年龄相关的记忆减退；饮食行为障碍，包括厌食症和贪食症；肥胖；丛集性头痛；偏头痛；疼痛；阿尔茨海默病；慢性阵发性偏头痛；与血管疾病相关的头痛；帕金森病，包括帕金森病性痴呆、神经阻滞剂诱发的帕金森综合症和迟发性运动障碍；内分泌障碍，如高催乳素血症；血管痉挛（特别是在脑血管中）；高血压；涉及运动和分泌变化的胃肠道疾病；性功能障碍，包括早泄；以及化学依赖性。
• Reverse hydroxamate inhibitors of matrix metalloproteinases
  申请人：Abbott Laboratories

  公开号：US06294573B1

  公开（公告）日：2001-09-25

  Compounds having the formula are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

  具有以下化学式的化合物是基质金属蛋白酶抑制剂。还公开了抑制基质金属蛋白酶的组合物和方法，用于在哺乳动物中抑制基质金属蛋白酶。
• Controllable construction of isoquinolinedione and isocoumarin scaffolds <i>via</i> Rh^III-catalyzed C–H annulation of <i>N</i>-tosylbenzamides with diazo compounds
  作者：Yanfei Liu、Jiaping Wu、Baiyang Qian、Yongjia Shang

  DOI：10.1039/c9ob01789e

  日期：——

  An efficient protocol for the synthesis of isoquinolinediones by Rh^III-catalyzed C–H activation/annulation/decarboxylation of N-tosylbenzamides with diazo compounds is reported.

  一种高效的协议报告了通过Rh^III催化的C-H活化/环化/脱羧反应，用双氮化合物与对甲苯磺酰苯甲酰胺合成异喹啉二酮。
• [EN] 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS DE 1,3,4-OXADIAZOLE SULFONAMIDE SERVANT D'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE COMPRENANT CEUX-CI
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2017018803A1

  公开（公告）日：2017-02-02

  The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.

  本发明涉及具有组蛋白去乙酰化酶6（HDAC6）抑制活性的新化合物，其立体异构体或药学上可接受的盐，其用于制备治疗药物，含有相同化合物的药物组合物，使用该组合物治疗疾病的方法，以及制备新化合物的方法。根据本发明，这些新化合物、其立体异构体或药学上可接受的盐具有组蛋白去乙酰化酶（HDAC）抑制活性，并且对于预防或治疗HDAC6介导的疾病有效。